Ackaert 2014

Current Status of Trial
Completed
Study Aim
Treatment Dementia
Study Design
RCT
Blinding
Double-blind
Intervention type
Pharmacological
Intervention
AZD5213 // Placebo
Dosage and Duration
4 weeks of treatment of three different doses of AZD5213
Absolute Number of Participants
81
Health Status/Diagnosis
Alzheimer disease (AD) // Mild Cognitive Impairment (MCI)
Primary outcomes
Sleep
Key Points
"both intensity of acquisition (u) and clearance of sleep (v) changed over time with a change in the ratio between the two intensities over time. No placebo effect was identified, while the drug concentration decreased u and v. AZD5213 plasma concentrations inhibited transitions to sleep more markedly than transitions to wakefulness. Simulations for various doses at steady state demonstrated that overall time awake increased with increasing dose with a maximum effect at doses above medium strength." Ackaert 2014